Search Results
1 - 12 of 13 matches
Sort by:
TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials
Presenter:
Angelo Biviano, MD, Patrick W. Serruys, Steven R. Bailey
November 1, 2017
PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis
Presenter:
David J. Cohen, Patrick W. Serruys
October 31, 2017
Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients
Presenter:
Michael J. Reardon
October 30, 2017
After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?
Presenter:
David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani
June 16, 2017
Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials
Presenter:
Alec S. Vahanian, Patrick T. O'Gara, Susheel K. Kodali
October 30, 2016
Highlights From PARTNER 2A in Intermediate-Risk Patients
Presenter:
Michael J. Mack
June 16, 2016
Updates from PARTNER 2A and Sapien 3 in Intermediate-Risk Patients
Presenter:
Ariel Finkelstein, Martin B. Leon, Neil E. Moat, Vinod H. Thourani
September 13, 2014
Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies
Presenter:
Jodi Akin
October 30, 2013
Status Update on the Randomized Moderate Risk AS Trials: PARTNER 2A
Presenter:
Martin Leon
October 27, 2013
Update from the Randomized PARTNER 2A Trial
Presenter:
Martin Leon
October 22, 2012